Contagion&reg Editorial Staff

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

Each week, the FDA posts relevant recalls and other patient safety information. We highlight some of these notices that may be clinically relevant.

Weekly, we identify which FDA recall announcements might be most clinically relevant.

A refresher on the week's developments in the infectious disease drug & medical device FDA approval pipeline.

A refresher on the week's developments in the infectious disease drug & medical device FDA approval pipeline.

FDA is working with local partners to continue the outbreak investigation.

Since the emergence of the SARS-CoV-2 pandemic in particular, news in the infectious disease drug and medical device pipeline has moved at an accelerated pace.

Broncolin S.A. de C.V is voluntarily recalling all lots of Herbacil Antiseptic Hand Sanitizer 70% Alcohol to the consumer level. The products are being recalled due to the potential presence of methanol (wood alcohol).

A round up of the week's infectious disease pipeline developments.

Weekly, we identify FDA announcements that pertain to infectious disease care. This week, FDA continued an investigation of undeclared wood alcohol contents in hand sanitizer.

A modeling study from Imperial College shows the COVID-19 pandemic may have significant effect on mortality among other infectious disease patients.

A modeling study from Imperial College shows the COVID-19 pandemic may require balancing with other infectious disease priorities.

New study findings shed light on the positive effects of baloxavir for preventing influenza spread in household settings.

In Mbandaka, an 11th outbreak of Ebola is emerging. This outbreak has renewed questions about what makes the virus such a challenge for Congolese society to reign in.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

Dr. Marc Pitasi, epidemiologist, discusses facilitators of routine HIV screening among primary care physicians.

Catch up with a review of our top drug pipeline stories from the past week.

Judith Feinberg, MD, FIDSA, describes ongoing investigation into the immune response from COVID-19.

A brief overview of our top stories.

Jonathan Spero, MD, discusses workplace safety in the time of SARS-CoV-2.

Recent concerns have been raised about a spike protein mutation in SARS-CoV-2. Are these fears grounded?

Judith Feinberg, MD, FIDSA, describes surprising outcomes in many COVID-19 cases among people living with HIV.

A brief overview of our recent coverage.

A brief summary of the latest news.

Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.

A brief on today's top ID news.

In a joint-interview, we discuss the PCV pipeline with Dr. Luwy Musey (of Merck & Co.) and Dr. Steven Pelton.

Video briefing on the day's top infectious disease news.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

An overview of today's top infectious disease stories.